Ozempic and Mounjaro are both FDA-approved for adults with type 2 diabetes, prescribed alongside diet and exercise to improve blood sugar control. Both are also widely used off-label for weight loss, distinct from their sister drugs Wegovy and Zepbound, which are the same active molecules approved specifically for weight management at different doses.
This page compares them primarily on their approved diabetes indication, using the outcomes their trials were actually built around — A1C and glycemic control — while noting where weight-loss context matters, since a lot of patients are prescribed one of these two hoping for both effects at once.
The one-line answer: both lower blood sugar and support weight loss in type 2 diabetes, and in the SURPASS-2 head-to-head trial tirzepatide (Mounjaro) produced somewhat greater average A1C reduction and weight loss than semaglutide 1 mg (Ozempic) — but the right choice still depends on your A1C target, tolerance and insurance formulary.
This guide provides general information and is not medical advice. Talk to your prescriber or pharmacist before starting, stopping, or changing any medication, supplement, or device used alongside GLP-1 therapy.
Ozempic vs Mounjaro at a Glance
| Category | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Molecule / mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| FDA-approved indication | Type 2 diabetes, adjunct to diet and exercise; also approved to reduce cardiovascular risk in adults with T2D and known heart disease | Type 2 diabetes, adjunct to diet and exercise |
| Dosing schedule | Once-weekly injection; titrated from 0.25 mg to a typical 1 or 2 mg maintenance dose | Once-weekly injection; titrated from 2.5 mg to a 5, 10 or 15 mg maintenance dose |
| Common side effects | Nausea, diarrhea, vomiting, constipation, injection-site reactions | Similar GI profile; nausea and diarrhea most common in trials |
| Trial evidence summary | SUSTAIN program for A1C and cardiovascular outcomes | SURPASS program; SURPASS-2 head-to-head found tirzepatide produced greater average A1C reduction and weight loss than semaglutide 1 mg |
| Who it may suit | Longer real-world prescribing history and an added cardiovascular-risk-reduction indication | Often considered when a larger average glycemic or weight effect is a priority, subject to tolerance and coverage |
Same Family, Different Approved Use Than Wegovy and Zepbound
Ozempic is the brand name for semaglutide dosed and approved for type 2 diabetes, typically at lower maintenance doses than its weight-management sibling Wegovy. Mounjaro is the brand name for tirzepatide dosed and approved for type 2 diabetes, using the same dose range as its weight-management sibling Zepbound. The approved-versus-off-label distinction has real insurance and access implications, which is worth understanding before assuming either drug is interchangeable with its sibling.
How They Lower Blood Sugar: One Incretin Pathway or Two
Both drugs work through glucose-dependent insulin secretion, suppressed glucagon release, and slowed gastric emptying — the core GLP-1 mechanism. Tirzepatide adds activity at the GIP receptor, a second incretin pathway that appears to contribute to its somewhat larger average effect on both A1C and weight in head-to-head data, though the precise relative contribution of each receptor is still being studied.
What SURPASS-2 Found
SURPASS-2 was a 40-week head-to-head trial comparing all three tirzepatide maintenance doses against semaglutide 1 mg in people with type 2 diabetes. It reported that each tirzepatide dose produced somewhat greater average A1C reduction and greater average weight loss than semaglutide 1 mg. Worth noting: semaglutide was tested at its diabetes-approved 1 mg dose, not the higher doses used for weight management, so some caution applies when generalizing the comparison beyond the diabetes indication tested.
Off-Label Weight Loss Use: What's Different From Wegovy/Zepbound
Off-label use means prescribing the diabetes-dosed medication (Ozempic or Mounjaro) to someone without diabetes, specifically for weight loss — which is not how those particular doses were studied. Insurance very rarely covers this use case. Their sibling drugs, Wegovy and Zepbound, were specifically studied and dosed for weight management and carry that FDA approval directly, which is generally the more straightforward pathway for someone whose primary goal is weight loss rather than diabetes management.
Side Effects and Safety Considerations
Both drugs share a similar GI side-effect profile — nausea, vomiting, diarrhea, constipation — concentrated around dose increases. Both carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies, and both carry a risk of pancreatitis and gallbladder problems. A personal or family history of medullary thyroid carcinoma or MEN 2 syndrome is generally a reason to avoid both.
Cost, Insurance and Access
Coverage for the diabetes-approved versions is often more straightforward to obtain than for the weight-management siblings when a patient has a documented type 2 diabetes diagnosis, but this still varies enormously by plan. As with any GLP-1 or dual-agonist drug, list price without insurance is high, and with-insurance cost depends entirely on your specific plan and formulary tier.
Supporting Products People on Either Medication Use
None of these are the medications themselves — prescription drugs aren't something to buy off a product list. These are the everyday supplies and supports that come up regardless of which of the two medications above someone ends up on.
A straightforward way to track how either medication is affecting your day-to-day glucose readings between A1C checks, useful context to bring to appointments.
View on Amazon →A low-cost, low-risk option many patients use during titration weeks when nausea is at its worst on either drug.
View on Amazon →Alcohol prep pads and rotation guidance help avoid the lumps and irritation that build up from injecting the same spot repeatedly on a weekly schedule.
View on Amazon →Useful for hitting a protein target on an appetite that both medications suppress, whichever one you're on.
View on Amazon →Questions to Bring to Your Prescriber
This page intentionally doesn't end in a verdict. Which medication is right for you depends on details a comparison page can't see — your labs, your history, your insurance plan, and how your body responds. These are the questions worth bringing to that conversation:
- Given my current A1C and health history, is there a reason to prefer the GLP-1-only or dual-receptor mechanism?
- Would I actually qualify for the weight-management-approved version of either drug instead of using the diabetes version off-label?
- What A1C target are we working toward, and on what timeline?
- How will we monitor for gallbladder, pancreatitis or thyroid-related symptoms?
- What is my insurance likely to cover, and does a prior authorization change that?
- If I don't reach target on the one we start with, what does switching between them look like?
Related GLP-1 Explained Guides
A comparison page answers which one. It doesn't cover everything else that comes up regardless of which option you're on:
- Preserving muscle during rapid weight loss — why the scale number isn't the whole story on either drug.
- Staying on a weekly injection schedule — reminder tools for a once-weekly dose that's easy to forget.
- The complete GLP-1 side-effect reference — what's common, what's rare, and what needs a call to your prescriber.